Virpax Enters into License Agreement to Develop High-Density Molecular Masking Spray Formulation (MMS019) for the Prevention of Respiratory Viruses
Nasal Powder Spray May Provide Barrier for Cell Transmission of Respiratory Infections [#item_full_content]Virpax Enters into License Agreement to Develop High-Density Molecular Masking Spray Formulation (MMS019) for the Prevention of Respiratory VirusesNasal Powder Spray May Provide Barrier for Cell Transmission of Respiratory InfectionsRSS Feed of Press Releases for VRPXRead MoreVirpax Enters into License Agreement to Develop High-Density Molecular Masking Spray Formulation (MMS019) for the Prevention of Respiratory VirusesNasal Powder Spray May Provide Barrier for Cell Transmission of Respiratory InfectionsVirpax Enters into License Agreement to Develop High-Density Molecular Masking Spray Formulation (MMS019) for the Prevention of Respiratory Viruses
Nasal Powder Spray May Provide Barrier for Cell Transmission of Respiratory Infections